<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <iati-identifier>SE-0-SE-29-2015-05868-666-43082</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Is Chronic Arsenic Poisoning Associated With Protein Aggregate Pathology?</narrative>
   <narrative xml:lang="SV">&#xC4;r kronisk arsenikf&#xF6;rgiftning f&#xF6;rknippad med proteinaggregationspatologi?</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="SV">Arsenik &#xE4;r ett grund&#xE4;mne som finns naturligt i jordskorpan och kan s&#xE5;ledes finnas i olika stora m&#xE4;ngder i jordm&#xE5;n och grundvatten. Arsenik &#xE4;r ett mycket skadligt &#xE4;mne f&#xF6;r m&#xE4;nniskor. Kronisk exponering dvs l&#xE5;ngtidsexponering av m&#xE4;nniskan f&#xF6;r arsenik via f&#xF6;dan kan resultera i flera mycket allvarliga sjukdomar s&#xE5;som hudf&#xF6;r&#xE4;ndringar, levercancer, diabetes, nervsjukdomar och hj&#xE4;rtsjukdomar. F&#xF6;rst&#xE5;elsen av sjukdomarnas uppkomst och arsenikexponering &#xE4;r mycket sparsamt f&#xF6;rst&#xE5;tt.  Arsenik har visats i laboratoriexperiment p&#xE5;verka m&#xE5;nga cellul&#xE4;ra processer och p&#xE5;visar tex DNA skador och oxidativ stress. Nyligen har flera experiment p&#xE5;visat p&#xE5;verkan p&#xE5; proteinfunktion och proteinveckning.  Felveckning av proteiner &#xE4;r starkt f&#xF6;rknippat med m&#xE5;nga allvarliga sjukdomar. Hit h&#xF6;r n&#xE5;gra mycket v&#xE4;lk&#xE4;nda sjukdomar, till exempel Alzheimers och Parkinsons sjukdom och &#xE4;ven sjukdomar som sk&#xF6;rbjugg och typ II diabetes r&#xE4;knas hit. Proteinermolekylerna klumpas ihop till proteinaggregat och skadar celler och organ d&#xE4;r de ansamlas. Mer och mer forskning tyder p&#xE5; att &#xE4;ven cancersjukdomar orsakas eller f&#xF6;rv&#xE4;rras av felveckade proteiner som dessutom kan spridas fr&#xE5;n cell till cell.  I Bangladesh f&#xF6;religger en av v&#xE4;rldens st&#xF6;rsta milj&#xF6;katastrofer. Stora delar av landets grundvattendep&#xE5;er &#xE4;r f&#xF6;rgiftade med naturligt f&#xF6;rekommande arsenik i olika kemiska former. Ber&#xE4;kningar har visat att m&#xE5;nga tiotals miljoner m&#xE4;nniskor f&#xF6;rses med vatten med halter av arsenik &#xF6;ver WHOs rekommenderade niv&#xE5;er. Ofta &#xE4;r dessa m&#xE4;nniskor fattiga och lever under primitiva f&#xF6;rh&#xE5;llanden p&#xE5; landsbygden. H&#xE4;lsouppf&#xF6;ljning f&#xF6;r denna grupp &#xE4;r s&#xE5;ledes mycket sparsam. Inom det f&#xF6;reslagna projektet planeras en vetenskaplig studie av hittills ostuderade sjukdomsmekanismer &#x2013; proteinaggregatsansamlingar i en grupp m&#xE4;nniskor i dessa utsatta omr&#xE5;den. Projektet &#xE4;r ett samverkansprojekt mellan Link&#xF6;pings universitet med expertis inom proteinveckning och dess sjudomsmekanismer och Dhaka Community Hospital som driver en sjukhusorganisation med specialisering inom v&#xE5;rd av arsenikexponerade patienter. F&#xF6;rhoppningen &#xE4;r att projektet kan leda till mer f&#xF6;rst&#xE5;else f&#xF6;r basala patologiska mekanismer vid kronisk arsenikf&#xF6;rgiftning som kommer st&#xE4;rka forskningen inom detta omr&#xE5;de samt i f&#xF6;rl&#xE4;ngningen f&#xF6;rb&#xE4;ttra v&#xE5;rden f&#xF6;r utsatta grupper i Bangladesh.</narrative>
   <narrative xml:lang="EN">Shallow tube-wells installed in Bangladesh in the 1970:ies and 80:ies were presumed to deliver safe drinking-water. Years later, the first cases of arsenic induced skin-lesions were identified and it was found that the drinking water was the source for the arsenic exposure. In Bangladesh alone, it is estimated that between 35-77 million people are at risk for arsenic derived health issues. Chronic arsenic poisoning results is a wide variety of pathological manifestations under the collective name arsenicosis with devastating consequences for afflicted individuals and for Bangladesh as a nation. It is established that protein misfolding is linked to a wide variety of diseases both as a cause and consequence. Misfolded proteins accumulate in many cell and organ types with apparent specificity for select proteins for certain diseases. The mechanisms involved are matters of intense research. Current research shows that self-propagation of misfolded proteins is a plausible mechanism for propagation of disease. Arsenic in various chemical forms is associated with inducing aberrant protein folding in laboratory experiments. With this indication it also follows that if arsenicosis is associated with protein aggregate pathology (e.g. amyloidosis) preventive measures mitigating the intake of arsenic may still propagate the misfolding process necessitating alternative therapies for afflicted individuals.</narrative>
  </description>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">Link&#xF6;pings universitet</narrative>
  </participating-org>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2016-01-01" type="2"></activity-date>
  <activity-date iso-date="2019-12-31" type="4"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="BD" percentage="100">
   <narrative xml:lang="EN">Bangladesh</narrative>
  </recipient-country>
  <sector code="430" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Other Multisector</narrative>
  </sector>
  <sector code="43082" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Research/scientific institutions</narrative>
  </sector>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">32723.6603751534</value>
  </budget>
  <budget>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-28"></period-end>
   <value currency="USD" value-date="2017-01-01">32760.0327600328</value>
  </budget>
  <budget>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">32219.4605541747</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-01-01"></transaction-date>
   <value currency="USD" value-date="2015-01-01">99652.4029278825</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-01-28"></transaction-date>
   <value currency="USD" value-date="2016-01-28">32723.6603751534</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-01-28"></transaction-date>
   <value currency="USD" value-date="2017-01-28">32760.0327600328</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-01-28"></transaction-date>
   <value currency="USD" value-date="2018-01-28">32219.4605541747</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <contribution contributionid="2015-05868" xmlns="http://sida.se/ns/contribution#"></contribution>
 </iati-activity>
</iati-activities>
